title: Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4.
abstract: This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) stage 4 in a prospective clinical trial. A total of 35 CKD-4 patients who had a baseline parathyroid hormone (iPTH) >150 pg/mL and had not received any vitamin D analog in the preceding 8 weeks were followed up at intervals of 6 weeks for 18 weeks on oral therapy with doxercalciferol. The starting dose was 1.5 μg/day, and the dose was increased in steps of 1 μg/day if iPTH did not decrease by at least 30% on the subsequent visit. Doxercalciferol was stopped temporarily if low iPTH (<70 pg/mL), hypercalcemia (>10.7 mg/dL), or severe hyperphosphatemia (>8.0 mg/dL) occurred, and was restarted at a lower dose on reversal of these abnormalities. Calcium acetate was the only phosphate binder used. Mean iPTH decreased by 35.4 ± 4.4% from 381.7 ± 31.3 pg/mL to 237.9 ± 25.7 pg/mL (P < 0.001). The proportion of patients who achieved 30% and 50% suppression of iPTH levels was 83% and 72%, respectively. Mean serum calcium, phosphorus, and calcium-phosphorus product values did not differ significantly from the baseline values. Four, two, and nine patients developed hypercalcemia, severe hyperphosphatemia, and high CaxP (>55), respectively. Almost all patients recovered to an acceptable level within 2 weeks of stopping doxercalciferol and adjusting the phosphate binder dose. In all, 21 patients required temporary stoppage of therapy. Most of them were restarted on therapy at a reduced dose during the study. It can, therefore, be concluded that doxercalciferol is effective in controlling SHPT in CKD-4 patients with an acceptable risk of hyperphosphatemia and hypercalcemia.
authors: Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors: P C
authors: PC
authors: Dheerendra
authors: V
authors: V
authors: Sakhuja
authors: H S
authors: HS
authors: Kohli
authors: V
authors: V
authors: Jha
keywords: Chronic kidney disease; doxercalciferol; parathyroid hormone; pre-dialysis; secondary hyperparathyroidism; vitamin D
references: Am J Kidney Dis. 2001 Mar;37(3):532-43
references: 11228177
references: Semin Nephrol. 1994 Mar;14(2):156-74
references: 8177982
references: Kidney Int. 1997 Jan;51(1):317-23
references: 8995749
references: J Clin Invest. 1984 Dec;74(6):2136-43
references: 6549016
references: Kidney Int. 1989 Feb;35(2):661-9
references: 2651758
references: Nephron. 1994;67(1):48-53
references: 8052367
references: N Engl J Med. 1989 Aug 3;321(5):274-9
references: 2631697
references: Am J Kidney Dis. 2000 Sep;36(3):550-61
references: 10977787
references: J Bone Miner Res. 1994 May;9(5):607-14
references: 8053388
references: Am J Kidney Dis. 2004 May;43(5):877-90
references: 15112179
references: Kidney Int Suppl. 1990 Sep;29:S22-7
references: 2214545
references: Am J Kidney Dis. 2000 Dec;36(6):1115-21
references: 11096034
references: J Clin Endocrinol Metab. 1988 Nov;67(5):929-36
references: 3182964
references: Am J Kidney Dis. 2006 Jan;47(1):149-56
references: 16377396